Breast Cancer Liquid Biopsy Market Size 2024-2028
The breast cancer liquid biopsy market size is forecast to increase by USD 534.8 million, at a CAGR of 18.06% between 2023 and 2028.
- The market is driven by the growing prevalence of breast cancer cases and initiatives to detect the disease at its early stages. Early detection significantly increases the chances of effective treatment and survival, making liquid biopsies an increasingly popular alternative to traditional tissue biopsies. However, the high cost of breast cancer liquid biopsies poses a significant challenge for both patients and healthcare systems. Despite this obstacle, the potential benefits of this advanced diagnostic tool are compelling, particularly in terms of improved patient outcomes and reduced healthcare costs through earlier intervention.
- Companies seeking to capitalize on this market opportunity must navigate the cost challenge by exploring innovative pricing models and partnerships with healthcare providers and insurers. Additionally, ongoing research and development efforts are expected to drive advancements in the accuracy and affordability of liquid biopsy technologies, further expanding their market potential.
What will be the Size of the Breast Cancer Liquid Biopsy Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample
The liquid biopsy market continues to evolve, driven by advancements in tumor heterogeneity understanding and the need for more accurate and timely cancer diagnosis and treatment. Mutation detection through liquid biopsy panels, utilizing next-generation sequencing and RNA sequencing, has emerged as a crucial tool in genetic analysis. Multiplexed assays and sample storage solutions enable efficient clinical validation and clinical trials. Industry collaboration and data analysis play significant roles in enhancing diagnostic accuracy and clinical utility. Precision oncology applications, such as personalized medicine, treatment response monitoring, and companion diagnostics, are gaining traction. Biomarker discovery and molecular profiling are key areas of focus, with circulating tumor cells and cell-free DNA offering valuable insights into the tumor microenvironment.
Sample preparation and regulatory approval are essential considerations for market penetration, while analytical validity and prognostic markers are crucial for ensuring the clinical utility of liquid biopsy technologies. Workflow optimization and targeted therapy are also essential aspects of this dynamic market. The ongoing quest for early detection and improved treatment outcomes fuels the adoption rates of these innovative solutions.
How is this Breast Cancer Liquid Biopsy Industry segmented?
The breast cancer liquid biopsy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Product Type
- Reagent kits
- Instruments
- Services
- Application
- Diagnostics
- Prognostics
- Risk Assessment
- Early Detection/Screening
- Treatment Selection
- Monitoring
- Circulating Biomaker
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Extracellular Vesicles (EVs)
- Other Circulating Biomarkers
- Geography
- North America
- Europe
- Middle East and Africa
- APAC
- South America
- Rest of World (ROW)
By Product Type Insights
The reagent kits segment is estimated to witness significant growth during the forecast period.
The market is experiencing significant growth, driven by the advancements in technology and increasing research in tumor heterogeneity and mutation detection. The reagent kits segment dominates this market, with the introduction of novel reagents enabling circulating biomarker analysis and target enrichment. This segment's growth is further fueled by increased funding for R&D, approvals of breast cancer liquid biopsy reagent kits, and a rising demand for these kits due to the surge in breast cancer liquid biopsy test procedures and the increasing prevalence of breast cancer worldwide. Additionally, next-generation sequencing, molecular profiling, and clinical validation play crucial roles in market expansion.
Industry collaboration, data analysis, and diagnostic accuracy are essential components of the market, with precision oncology, personalized medicine, and companion diagnostics gaining traction. Sample preparation, tumor microenvironment, early detection, and treatment response monitoring are also key areas of focus. Market penetration is boosted by regulatory approval, workflow optimization, and the adoption of analytical validity and prognostic markers such as circulating tumor cells and cell-free DNA. The market's evolution is further driven by RNA sequencing, targeted therapy, and intellectual property development.
Request Free Sample
The Reagent kits segment was valued at USD 156.90 million in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 55% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The North American market is poised for steady expansion during the forecast period. This region's growth is primarily fueled by the healthcare sector's increasing adoption of advanced technologies, substantial healthcare expenditure, rising breast cancer prevalence, and heightened patient awareness regarding breast cancer screening. Furthermore, the presence of numerous companies manufacturing breast cancer liquid biopsy kits and products, as well as technological advancements in biopsy techniques, are significant market growth drivers. Molecular profiling, genetic analysis, and diagnostic accuracy are key factors propelling the market's growth. Next-generation sequencing and RNA sequencing are increasingly being utilized for biomarker discovery and personalized medicine, including targeted therapy and companion diagnostics.
Industry collaboration and clinical trials are crucial for clinical validation and regulatory approval, ensuring analytical validity and clinical utility. Sample preparation, tumor microenvironment analysis, and early detection are essential aspects of the market. Circulating tumor cells, cell-free DNA, and prognostic markers are critical biomarkers for treatment response monitoring and precision oncology. Market penetration is influenced by the adoption rates of these advanced diagnostic techniques and the integration of liquid biopsy into clinical workflows for optimal workflow optimization. Intellectual property protection is essential for market players, ensuring the protection of their innovative technologies and products. The market's evolution is characterized by continuous technological advancements, clinical validation, and regulatory approvals, making it an exciting and dynamic field in precision oncology.
Market Dynamics
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise in the adoption of Breast Cancer Liquid Biopsy Industry?
- The increasing prevalence of breast cancer is the primary factor fueling market growth in this sector.
- Breast cancer is a significant health concern globally, accounting for a considerable number of deaths worldwide. Among various types of cancer, breast cancer is the most common among women, with a higher prevalence in the geriatric population. According to recent data, approximately 9% of the global female population is aged 65 and above, making them more susceptible to breast cancer. Younger women are also at risk, as the CDC reported that around 12% of new breast cancer cases in the US occurred in women under 45 years old in July 2021. The advancement in precision oncology and the growing focus on workflow optimization in healthcare have led to the increasing adoption of breast cancer liquid biopsy tests.
- These tests provide valuable insights into the disease's genetic makeup, enabling more accurate diagnosis and personalized treatment plans. Precision oncology relies on analytical validity, which is crucial for the accurate detection of prognostic markers such as circulating tumor cells (CTCs) and DNA sequencing. Intellectual property plays a vital role in the market, with companies investing heavily in research and development to secure patents and protect their intellectual property. Regulatory approval is another critical factor, as these tests must meet stringent regulatory requirements to ensure their safety and efficacy. Despite these challenges, the market is expected to grow significantly due to its potential to revolutionize cancer diagnosis and treatment.
What are the market trends shaping the Breast Cancer Liquid Biopsy Industry?
- The detection of breast cancer at its early stages is gaining significant attention in the market. Professionals predict an upward trend in the development and implementation of programs designed for early breast cancer detection.
- Liquid biopsy, a revolutionary diagnostic approach in cancer detection, is gaining significant traction in the medical community due to its ability to identify tumor heterogeneity and mutations. This non-invasive technique employs multiplexed assays and next-generation sequencing to analyze circulating tumor cells and DNA fragments in a patient's bloodstream. Fueled by industry collaboration and advancements in technology, liquid biopsy panels are becoming increasingly valuable tools for early detection and personalized treatment plans. Sample storage and data analysis are crucial aspects of these panels, ensuring accurate and reliable results. Government and private organizations have recognized the potential of liquid biopsy and have provided funding and grants to support research and development.
- For instance, the European Commission has funded projects like BRIDGES and B-CAST, which focus on next-generation sequencing and breast cancer stratification, respectively. These initiatives aim to provide better solutions for breast cancer screening and improve preventive care by identifying women at high risk and offering precise identification of their chances of developing breast cancer. In conclusion, the advancements in liquid biopsy technology and the support from various funding sources are driving the development of innovative products that will significantly impact breast cancer screening and patient care. These tools will enable earlier detection, personalized treatment plans, and improved preventive measures, ultimately leading to better outcomes for patients.
What challenges does the Breast Cancer Liquid Biopsy Industry face during its growth?
- The exorbitant cost of breast biopsies poses a significant challenge to the growth of the industry. This expense, a notable concern for both healthcare providers and patients, warrants ongoing attention and potential solutions to ensure accessibility and affordability for necessary diagnostic procedures.
- Breast cancer is a significant health concern worldwide, leading to an increased focus on advanced diagnostic tools for early detection and personalized treatment. Among these, liquid biopsy is emerging as a promising solution in breast cancer diagnosis and treatment response monitoring. This minimally invasive procedure involves analyzing various biomarkers, including genetic material and proteins, present in bodily fluids. Liquid biopsy offers several advantages over traditional diagnostic methods, such as diagnostic accuracy, molecular profiling, and clinical validation through clinical trials. RNA sequencing is a crucial technology used in liquid biopsy to identify genetic mutations and understand the molecular mechanisms of breast cancer.
- This information is essential for treatment planning and monitoring treatment response in real-time, paving the way for personalized medicine. The market penetration of breast cancer liquid biopsy is expected to grow significantly due to its potential to improve patient outcomes and reduce healthcare costs. Clinical validation and ongoing clinical trials further strengthen the credibility of this innovative diagnostic approach.
Exclusive Customer Landscape
The breast cancer liquid biopsy market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the breast cancer liquid biopsy market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, breast cancer liquid biopsy market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Adaptive Biotechnologies - This company specializes in advanced breast cancer diagnostics through a liquid biopsy approach. The innovative technology employed identifies Breast Tumor Antigen, which plays a crucial role in safeguarding mucous membranes, regulating signal transduction, and enhancing the immune system's response.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Adaptive Biotechnologies
- Agena Bioscience Inc.
- Bio-Rad Laboratories Inc.
- Biocept, Inc.
- Biodesix, Inc.
- Cynvenio Biosystems, Inc.
- Epic Sciences
- F. Hoffmann-La Roche Ltd. (including Foundation Medicine, Inc.)
- Fluxion Biosciences, Inc.
- Guardant Health Inc.
- Illumina Inc.
- Janssen Diagnostics
- Menarini Silicon Biosystems
- Myriad Genetics Inc.
- Natera, Inc.
- NeoGenomics Laboratories Inc.
- QIAGEN N.V.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Vortex Biosciences
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Breast Cancer Liquid Biopsy Market
- In February 2023, Qiagen NV, a leading provider of sample and assay technologies, announced the launch of its new Circulating Tumor DNA (ctDNA) assay, Gabriela Star, for the detection and monitoring of breast cancer. This assay utilizes next-generation sequencing technology and is designed to identify mutations in circulating tumor DNA from a single blood draw (Qiagen Press Release, 2023).
- In March 2024, Illumina, Inc., a global leader in genomic sequencing and array-based solutions, entered into a strategic collaboration with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize a liquid biopsy test for early detection and monitoring of breast cancer. This collaboration combines Illumina's expertise in genomic sequencing with Merck's clinical and commercial capabilities (Illumina Press Release, 2024).
- In May 2024, Grail, Inc., a healthcare company focused on cancer detection, raised USD1.8 billion in a Series D funding round. The funds will be used to further develop and commercialize its liquid biopsy test, Galleri, for the early detection of multiple cancer types, including breast cancer (Grail Press Release, 2024).
- In January 2025, the U.S. Food and Drug Administration (FDA) granted marketing authorization to Guardant Health, Inc. For its liquid biopsy test, Guardant360 Lung-1, for the detection of recurrence and resistance mechanisms in advanced non-small cell lung cancer. This approval marks a significant milestone for the liquid biopsy market, as it is the first FDA approval for a multi-biomarker liquid biopsy test in oncology (Guardant Health Press Release, 2025). Although not directly related to breast cancer, this approval is expected to further validate the liquid biopsy technology and accelerate its adoption in breast cancer diagnostics.
Research Analyst Overview
- The market is experiencing significant advancements in the realm of disease management and cancer screening. The integration of digital PCR and next-generation sequencing technologies enables the detection of epigenetic markers and protein biomarkers, facilitating early risk assessment and disease progression monitoring. Artificial intelligence and machine learning algorithms are utilized to analyze Big Data derived from these tests, enhancing clinical decision support and personalized therapeutic targets. Patient education plays a crucial role in the adoption of liquid biopsies, as they offer improved quality of life and reduced healthcare costs associated with invasive procedures. Tumor burden and cancer stem cells can be effectively monitored through these tests, allowing for more accurate assessment of patient outcomes and informed clinical interventions.
- Data Security and ethical considerations are essential aspects of the market, as sensitive patient information is handled. Point-of-care testing and microfluidic devices are gaining popularity due to their convenience and potential for targeted drug delivery. The market is further fueled by the development of new therapeutic targets and advancements in disease management strategies. The integration of liquid biopsies into public health initiatives and cancer screening programs holds immense potential for improving patient outcomes and reducing healthcare costs. However, ongoing research is required to address the challenges of disease progression and ensure the accuracy and reliability of these tests.
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Breast Cancer Liquid Biopsy Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
141
|
|
Base year
|
2023
|
|
Historic period
|
2018-2022 |
|
Forecast period
|
2024-2028
|
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 18.06%
|
|
Market growth 2024-2028
|
USD 534.8 million
|
|
Market structure
|
Fragmented
|
|
YoY growth 2023-2024(%)
|
15.55
|
|
Key countries
|
US, Canada, Germany, UK, Italy, France, China, India, Japan, Brazil, Egypt, UAE, Oman, Argentina, KSA, UAE, Brazil, and Rest of World (ROW)
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Breast Cancer Liquid Biopsy Market Research and Growth Report?
- CAGR of the Breast Cancer Liquid Biopsy industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the breast cancer liquid biopsy market growth of industry companies
We can help! Our analysts can customize this breast cancer liquid biopsy market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 2.2 Market characteristics
- Market characteristics analysis
3 Market Sizing
- 3.1 Market definition
- Offerings of companies included in the market definition
- 3.2 Market segment analysis
- 3.4 Market outlook: Forecast for 2023-2028
- Chart on Global - Market size and forecast 2023-2028 ($ million)
- Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global Breast Cancer Liquid Biopsy Market 2018 - 2022
- Historic Market Size - Data Table on Global Breast Cancer Liquid Biopsy Market 2018 - 2022 ($ million)
- 4.2 Product Type segment analysis 2018 - 2022
- Historic Market Size - Product Type Segment 2018 - 2022 ($ million)
- 4.3 Geography segment analysis 2018 - 2022
- Historic Market Size - Geography Segment 2018 - 2022 ($ million)
- 4.4 Country segment analysis 2018 - 2022
- Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product Type
- 6.1 Market segments
- Chart on Product Type - Market share (2023-2028) (%)
- Data Table on Product Type - Market share (2023-2028) (%)
- 6.2 Comparison by Product Type
- Chart on Comparison by Product Type
- Data Table on Comparison by Product Type
- 6.3 Reagent kits - Market size and forecast (2023-2028)
- Chart on Reagent kits - Market size and forecast (2023-2028) ($ million)
- Data Table on Reagent kits - Market size and forecast (2023-2028) ($ million)
- Chart on Reagent kits - Year-over-year growth (2023-2028) (%)
- Data Table on Reagent kits - Year-over-year growth (2023-2028) (%)
- 6.4 Instruments - Market size and forecast (2023-2028)
- Chart on Instruments - Market size and forecast (2023-2028) ($ million)
- Data Table on Instruments - Market size and forecast (2023-2028) ($ million)
- Chart on Instruments - Year-over-year growth (2023-2028) (%)
- Data Table on Instruments - Year-over-year growth (2023-2028) (%)
- 6.5 Services - Market size and forecast (2023-2028)
- Chart on Services - Market size and forecast (2023-2028) ($ million)
- Data Table on Services - Market size and forecast (2023-2028) ($ million)
- Chart on Services - Year-over-year growth (2023-2028) (%)
- Data Table on Services - Year-over-year growth (2023-2028) (%)
- 6.6 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
- Data Table on Market opportunity by Product Type ($ million)
7 Market Segmentation by Application
- 7.1 Market segments
- Chart on Application - Market share (2023-2028) (%)
- Data Table on Application - Market share (2023-2028) (%)
- 7.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 7.3 Diagnostics - Market size and forecast (2023-2028)
- Chart on Diagnostics - Market size and forecast (2023-2028) ($ million)
- Data Table on Diagnostics - Market size and forecast (2023-2028) ($ million)
- Chart on Diagnostics - Year-over-year growth (2023-2028) (%)
- Data Table on Diagnostics - Year-over-year growth (2023-2028) (%)
- 7.4 Prognostics - Market size and forecast (2023-2028)
- Chart on Prognostics - Market size and forecast (2023-2028) ($ million)
- Data Table on Prognostics - Market size and forecast (2023-2028) ($ million)
- Chart on Prognostics - Year-over-year growth (2023-2028) (%)
- Data Table on Prognostics - Year-over-year growth (2023-2028) (%)
- 7.5 Risk Assessment - Market size and forecast (2023-2028)
- Chart on Risk Assessment - Market size and forecast (2023-2028) ($ million)
- Data Table on Risk Assessment - Market size and forecast (2023-2028) ($ million)
- Chart on Risk Assessment - Year-over-year growth (2023-2028) (%)
- Data Table on Risk Assessment - Year-over-year growth (2023-2028) (%)
- 7.6 Early Detection/Screening - Market size and forecast (2023-2028)
- Chart on Early Detection/Screening - Market size and forecast (2023-2028) ($ million)
- Data Table on Early Detection/Screening - Market size and forecast (2023-2028) ($ million)
- Chart on Early Detection/Screening - Year-over-year growth (2023-2028) (%)
- Data Table on Early Detection/Screening - Year-over-year growth (2023-2028) (%)
- 7.7 Treatment Selection - Market size and forecast (2023-2028)
- Chart on Treatment Selection - Market size and forecast (2023-2028) ($ million)
- Data Table on Treatment Selection - Market size and forecast (2023-2028) ($ million)
- Chart on Treatment Selection - Year-over-year growth (2023-2028) (%)
- Data Table on Treatment Selection - Year-over-year growth (2023-2028) (%)
- 7.8 Monitoring - Market size and forecast (2023-2028)
- Chart on Monitoring - Market size and forecast (2023-2028) ($ million)
- Data Table on Monitoring - Market size and forecast (2023-2028) ($ million)
- Chart on Monitoring - Year-over-year growth (2023-2028) (%)
- Data Table on Monitoring - Year-over-year growth (2023-2028) (%)
- 7.9 Market opportunity by Application
- Market opportunity by Application ($ million)
- Data Table on Market opportunity by Application ($ million)
8 Market Segmentation by Circulating Biomaker
- 8.1 Market segments
- Chart on Circulating Biomaker - Market share (2023-2028) (%)
- Data Table on Circulating Biomaker - Market share (2023-2028) (%)
- 8.2 Comparison by Circulating Biomaker
- Chart on Comparison by Circulating Biomaker
- Data Table on Comparison by Circulating Biomaker
- 8.3 Circulating Tumor Cells (CTCs) - Market size and forecast (2023-2028)
- Chart on Circulating Tumor Cells (CTCs) - Market size and forecast (2023-2028) ($ million)
- Data Table on Circulating Tumor Cells (CTCs) - Market size and forecast (2023-2028) ($ million)
- Chart on Circulating Tumor Cells (CTCs) - Year-over-year growth (2023-2028) (%)
- Data Table on Circulating Tumor Cells (CTCs) - Year-over-year growth (2023-2028) (%)
- 8.4 Circulating Tumor DNA (ctDNA) - Market size and forecast (2023-2028)
- Chart on Circulating Tumor DNA (ctDNA) - Market size and forecast (2023-2028) ($ million)
- Data Table on Circulating Tumor DNA (ctDNA) - Market size and forecast (2023-2028) ($ million)
- Chart on Circulating Tumor DNA (ctDNA) - Year-over-year growth (2023-2028) (%)
- Data Table on Circulating Tumor DNA (ctDNA) - Year-over-year growth (2023-2028) (%)
- 8.5 Extracellular Vesicles (EVs) - Market size and forecast (2023-2028)
- Chart on Extracellular Vesicles (EVs) - Market size and forecast (2023-2028) ($ million)
- Data Table on Extracellular Vesicles (EVs) - Market size and forecast (2023-2028) ($ million)
- Chart on Extracellular Vesicles (EVs) - Year-over-year growth (2023-2028) (%)
- Data Table on Extracellular Vesicles (EVs) - Year-over-year growth (2023-2028) (%)
- 8.6 Other Circulating Biomarkers - Market size and forecast (2023-2028)
- Chart on Other Circulating Biomarkers - Market size and forecast (2023-2028) ($ million)
- Data Table on Other Circulating Biomarkers - Market size and forecast (2023-2028) ($ million)
- Chart on Other Circulating Biomarkers - Year-over-year growth (2023-2028) (%)
- Data Table on Other Circulating Biomarkers - Year-over-year growth (2023-2028) (%)
- 8.7 Market opportunity by Circulating Biomaker
- Market opportunity by Circulating Biomaker ($ million)
- Data Table on Market opportunity by Circulating Biomaker ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- Chart on Application - Market share (2023-2028) (%)
- Data Table on Application - Market share (2023-2028) (%)
- 9.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 9.3 Diagnostics - Market size and forecast (2023-2028)
- Chart on Diagnostics - Market size and forecast (2023-2028) ($ million)
- Data Table on Diagnostics - Market size and forecast (2023-2028) ($ million)
- Chart on Diagnostics - Year-over-year growth (2023-2028) (%)
- Data Table on Diagnostics - Year-over-year growth (2023-2028) (%)
- 9.4 Prognostics - Market size and forecast (2023-2028)
- Chart on Prognostics - Market size and forecast (2023-2028) ($ million)
- Data Table on Prognostics - Market size and forecast (2023-2028) ($ million)
- Chart on Prognostics - Year-over-year growth (2023-2028) (%)
- Data Table on Prognostics - Year-over-year growth (2023-2028) (%)
- 9.5 Risk Assessment - Market size and forecast (2023-2028)
- Chart on Risk Assessment - Market size and forecast (2023-2028) ($ million)
- Data Table on Risk Assessment - Market size and forecast (2023-2028) ($ million)
- Chart on Risk Assessment - Year-over-year growth (2023-2028) (%)
- Data Table on Risk Assessment - Year-over-year growth (2023-2028) (%)
- 9.6 Early Detection/Screening - Market size and forecast (2023-2028)
- Chart on Early Detection/Screening - Market size and forecast (2023-2028) ($ million)
- Data Table on Early Detection/Screening - Market size and forecast (2023-2028) ($ million)
- Chart on Early Detection/Screening - Year-over-year growth (2023-2028) (%)
- Data Table on Early Detection/Screening - Year-over-year growth (2023-2028) (%)
- 9.7 Treatment Selection - Market size and forecast (2023-2028)
- Chart on Treatment Selection - Market size and forecast (2023-2028) ($ million)
- Data Table on Treatment Selection - Market size and forecast (2023-2028) ($ million)
- Chart on Treatment Selection - Year-over-year growth (2023-2028) (%)
- Data Table on Treatment Selection - Year-over-year growth (2023-2028) (%)
- 9.8 Monitoring - Market size and forecast (2023-2028)
- Chart on Monitoring - Market size and forecast (2023-2028) ($ million)
- Data Table on Monitoring - Market size and forecast (2023-2028) ($ million)
- Chart on Monitoring - Year-over-year growth (2023-2028) (%)
- Data Table on Monitoring - Year-over-year growth (2023-2028) (%)
- 9.9 Market opportunity by Application
- Market opportunity by Application ($ million)
- Data Table on Market opportunity by Application ($ million)
10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2023-2028 (%)
- Data Table on Market share by geography 2023-2028 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2023-2028
- Chart on North America - Market size and forecast 2023-2028 ($ million)
- Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Chart on North America - Year-over-year growth 2023-2028 (%)
- Data Table on North America - Year-over-year growth 2023-2028 (%)
- 11.4 Europe - Market size and forecast 2023-2028
- Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Chart on Europe - Year-over-year growth 2023-2028 (%)
- Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 11.5 Asia - Market size and forecast 2023-2028
- Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Chart on Asia - Year-over-year growth 2023-2028 (%)
- Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 11.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 11.7 US - Market size and forecast 2023-2028
- Chart on US - Market size and forecast 2023-2028 ($ million)
- Data Table on US - Market size and forecast 2023-2028 ($ million)
- Chart on US - Year-over-year growth 2023-2028 (%)
- Data Table on US - Year-over-year growth 2023-2028 (%)
- 11.8 Germany - Market size and forecast 2023-2028
- Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Chart on Germany - Year-over-year growth 2023-2028 (%)
- Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 11.9 UK - Market size and forecast 2023-2028
- Chart on UK - Market size and forecast 2023-2028 ($ million)
- Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Chart on UK - Year-over-year growth 2023-2028 (%)
- Data Table on UK - Year-over-year growth 2023-2028 (%)
- 11.10 Canada - Market size and forecast 2023-2028
- Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Chart on Canada - Year-over-year growth 2023-2028 (%)
- Data Table on Canada - Year-over-year growth 2023-2028 (%)
- 11.11 France - Market size and forecast 2023-2028
- Chart on France - Market size and forecast 2023-2028 ($ million)
- Data Table on France - Market size and forecast 2023-2028 ($ million)
- Chart on France - Year-over-year growth 2023-2028 (%)
- Data Table on France - Year-over-year growth 2023-2028 (%)
- 11.12 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
- 11.13 Italy - Market size and forecast (2023-2028)
- Chart on Italy - Market size and forecast (2023-2028) ($ million)
- Data Table on Italy - Market size and forecast (2023-2028) ($ million)
- Chart on Italy - Year-over-year growth (2023-2028) (%)
- Data Table on Italy - Year-over-year growth (2023-2028) (%)
- 11.14 China - Market size and forecast (2023-2028)
- Chart on China - Market size and forecast (2023-2028) ($ million)
- Data Table on China - Market size and forecast (2023-2028) ($ million)
- Chart on China - Year-over-year growth (2023-2028) (%)
- Data Table on China - Year-over-year growth (2023-2028) (%)
- 11.15 India - Market size and forecast (2023-2028)
- Chart on India - Market size and forecast (2023-2028) ($ million)
- Data Table on India - Market size and forecast (2023-2028) ($ million)
- Chart on India - Year-over-year growth (2023-2028) (%)
- Data Table on India - Year-over-year growth (2023-2028) (%)
- 11.16 Japan - Market size and forecast (2023-2028)
- Chart on Japan - Market size and forecast (2023-2028) ($ million)
- Data Table on Japan - Market size and forecast (2023-2028) ($ million)
- Chart on Japan - Year-over-year growth (2023-2028) (%)
- Data Table on Japan - Year-over-year growth (2023-2028) (%)
- 11.17 Brazil - Market size and forecast (2023-2028)
- Chart on Brazil - Market size and forecast (2023-2028) ($ million)
- Data Table on Brazil - Market size and forecast (2023-2028) ($ million)
- Chart on Brazil - Year-over-year growth (2023-2028) (%)
- Data Table on Brazil - Year-over-year growth (2023-2028) (%)
- 11.18 Egypt - Market size and forecast (2023-2028)
- Chart on Egypt - Market size and forecast (2023-2028) ($ million)
- Data Table on Egypt - Market size and forecast (2023-2028) ($ million)
- Chart on Egypt - Year-over-year growth (2023-2028) (%)
- Data Table on Egypt - Year-over-year growth (2023-2028) (%)
- 11.19 UAE - Market size and forecast (2023-2028)
- Chart on UAE - Market size and forecast (2023-2028) ($ million)
- Data Table on UAE - Market size and forecast (2023-2028) ($ million)
- Chart on UAE - Year-over-year growth (2023-2028) (%)
- Data Table on UAE - Year-over-year growth (2023-2028) (%)
- 11.20 Oman - Market size and forecast (2023-2028)
- Chart on Oman - Market size and forecast (2023-2028) ($ million)
- Data Table on Oman - Market size and forecast (2023-2028) ($ million)
- Chart on Oman - Year-over-year growth (2023-2028) (%)
- Data Table on Oman - Year-over-year growth (2023-2028) (%)
- 11.21 Argentina - Market size and forecast (2023-2028)
- Chart on Argentina - Market size and forecast (2023-2028) ($ million)
- Data Table on Argentina - Market size and forecast (2023-2028) ($ million)
- Chart on Argentina - Year-over-year growth (2023-2028) (%)
- Data Table on Argentina - Year-over-year growth (2023-2028) (%)
- 11.22 KSA - Market size and forecast (2023-2028)
- Chart on KSA - Market size and forecast (2023-2028) ($ million)
- Data Table on KSA - Market size and forecast (2023-2028) ($ million)
- Chart on KSA - Year-over-year growth (2023-2028) (%)
- Data Table on KSA - Year-over-year growth (2023-2028) (%)
12 Drivers, Challenges, and Opportunity/Restraints
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2023 and 2028
- 12.4 Market opportunities/restraints
13 Competitive Landscape
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14.2 Market positioning of companies
- Matrix on companies position and classification
- 14.3 Adaptive Biotechnologies
- Adaptive Biotechnologies - Overview
- Adaptive Biotechnologies - Product / Service
- Adaptive Biotechnologies - Key offerings
- 14.4 Agena Bioscience Inc.
- Agena Bioscience Inc. - Overview
- Agena Bioscience Inc. - Product / Service
- Agena Bioscience Inc. - Key offerings
- 14.5 Bio-Rad Laboratories Inc.
- Bio-Rad Laboratories Inc. - Overview
- Bio-Rad Laboratories Inc. - Product / Service
- Bio-Rad Laboratories Inc. - Key offerings
- 14.6 Biocept, Inc.
- Biocept, Inc. - Overview
- Biocept, Inc. - Product / Service
- Biocept, Inc. - Key offerings
- 14.7 Biodesix, Inc.
- Biodesix, Inc. - Overview
- Biodesix, Inc. - Product / Service
- Biodesix, Inc. - Key offerings
- 14.8 Cynvenio Biosystems, Inc.
- Cynvenio Biosystems, Inc. - Overview
- Cynvenio Biosystems, Inc. - Product / Service
- Cynvenio Biosystems, Inc. - Key offerings
- 14.9 Epic Sciences
- Epic Sciences - Overview
- Epic Sciences - Product / Service
- Epic Sciences - Key offerings
- 14.10 F. Hoffmann-La Roche Ltd. (including Foundation Medicine, Inc.)
- F. Hoffmann-La Roche Ltd. (including Foundation Medicine, Inc.) - Overview
- F. Hoffmann-La Roche Ltd. (including Foundation Medicine, Inc.) - Product / Service
- F. Hoffmann-La Roche Ltd. (including Foundation Medicine, Inc.) - Key offerings
- 14.11 Fluxion Biosciences, Inc.
- Fluxion Biosciences, Inc. - Overview
- Fluxion Biosciences, Inc. - Product / Service
- Fluxion Biosciences, Inc. - Key offerings
- 14.12 Guardant Health Inc.
- Guardant Health Inc. - Overview
- Guardant Health Inc. - Product / Service
- Guardant Health Inc. - Key offerings
- 14.13 Illumina Inc.
- Illumina Inc. - Overview
- Illumina Inc. - Product / Service
- Illumina Inc. - Key offerings
- 14.14 Janssen Diagnostics
- Janssen Diagnostics - Overview
- Janssen Diagnostics - Product / Service
- Janssen Diagnostics - Key offerings
- 14.15 Menarini Silicon Biosystems
- Menarini Silicon Biosystems - Overview
- Menarini Silicon Biosystems - Product / Service
- Menarini Silicon Biosystems - Key offerings
- 14.16 Myriad Genetics Inc.
- Myriad Genetics Inc. - Overview
- Myriad Genetics Inc. - Product / Service
- Myriad Genetics Inc. - Key offerings
- 14.17 Natera, Inc.
- Natera, Inc. - Overview
- Natera, Inc. - Product / Service
- Natera, Inc. - Key offerings
- 14.18 NeoGenomics Laboratories Inc.
- NeoGenomics Laboratories Inc. - Overview
- NeoGenomics Laboratories Inc. - Product / Service
- NeoGenomics Laboratories Inc. - Key offerings
- 14.19 QIAGEN N.V.
- QIAGEN N.V. - Overview
- QIAGEN N.V. - Product / Service
- QIAGEN N.V. - Key offerings
- 14.20 Sysmex Corporation
- Sysmex Corporation - Overview
- Sysmex Corporation - Product / Service
- Sysmex Corporation - Key offerings
- 14.21 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Product / Service
- Thermo Fisher Scientific Inc. - Key offerings
- 14.22 Vortex Biosciences
- Vortex Biosciences - Overview
- Vortex Biosciences - Product / Service
- Vortex Biosciences - Key offerings
- 14.23 Bio Rad Laboratories Inc.
- Bio Rad Laboratories Inc. - Overview
- Bio Rad Laboratories Inc. - Product / Service
- Bio Rad Laboratories Inc. - Key offerings
- 14.24 Biocept Inc.
- Biocept Inc. - Overview
- Biocept Inc. - Product / Service
- Biocept Inc. - Key offerings
- 14.25 Biodesix Inc.
- Biodesix Inc. - Overview
- Biodesix Inc. - Product / Service
- Biodesix Inc. - Key offerings
- 14.26 Cardiff Oncology Inc.
- Cardiff Oncology Inc. - Overview
- Cardiff Oncology Inc. - Product / Service
- Cardiff Oncology Inc. - Key offerings
- 14.27 Epic Sciences Inc.
- Epic Sciences Inc. - Overview
- Epic Sciences Inc. - Product / Service
- Epic Sciences Inc. - Key offerings
- 14.28 Exact Sciences Corp.
- Exact Sciences Corp. - Overview
- Exact Sciences Corp. - Product / Service
- Exact Sciences Corp. - Key offerings
- 14.29 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Product / Service
- F. Hoffmann La Roche Ltd. - Key offerings
- 14.30 Fluxion Biosciences Inc.
- Fluxion Biosciences Inc. - Overview
- Fluxion Biosciences Inc. - Product / Service
- Fluxion Biosciences Inc. - Key offerings
- 14.31 Guardant Health Inc.
- Guardant Health Inc. - Overview
- Guardant Health Inc. - Product / Service
- Guardant Health Inc. - Key offerings
- 14.32 Illumina Inc.
- Illumina Inc. - Overview
- Illumina Inc. - Product / Service
- Illumina Inc. - Key offerings
- 14.33 Isogen Life Science BV
- Isogen Life Science BV - Overview
- Isogen Life Science BV - Product / Service
- Isogen Life Science BV - Key offerings
- 14.34 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Product / Service
- Johnson and Johnson Services Inc. - Key offerings
- 14.35 Lucence Health Inc.
- Lucence Health Inc. - Overview
- Lucence Health Inc. - Product / Service
- Lucence Health Inc. - Key offerings
- 14.36 Menarini Silicon Biosystems SpA
- Menarini Silicon Biosystems SpA - Overview
- Menarini Silicon Biosystems SpA - Product / Service
- Menarini Silicon Biosystems SpA - Key offerings
- 14.37 MiRXES Pte Ltd.
- MiRXES Pte Ltd. - Overview
- MiRXES Pte Ltd. - Product / Service
- MiRXES Pte Ltd. - Key offerings
- 14.38 Myriad Genetics Inc.
- Myriad Genetics Inc. - Overview
- Myriad Genetics Inc. - Product / Service
- Myriad Genetics Inc. - Key offerings
- 14.39 NeoGenomics Laboratories Inc.
- NeoGenomics Laboratories Inc. - Overview
- NeoGenomics Laboratories Inc. - Product / Service
- NeoGenomics Laboratories Inc. - Key offerings
- 14.40 QIAGEN NV
- QIAGEN NV - Overview
- QIAGEN NV - Product / Service
- QIAGEN NV - Key offerings
- 14.41 Sysmex Inostics Inc.
- Sysmex Inostics Inc. - Overview
- Sysmex Inostics Inc. - Product / Service
- Sysmex Inostics Inc. - Key offerings
- 14.42 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Product / Service
- Thermo Fisher Scientific Inc. - Key offerings
15 Appendix
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
